Clinical trials: Carcinoma, Transitional Cell
Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.
- Conditions
- Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive
- Trial name
- NCT06714617
- Testing
- BL-M17D1
- Where
- 9 sites in United States
- Volunteers
- 3 people
- Sponsor
- SystImmune Inc.
Bladder Transitional Cell Carcinoma Stage IV
JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin
This study is assessing the combination of well known cytotoxics with a novel anti-cancer agent that could be administered as monotherapy without renal toxicity in patients with renal impairment presenting with advanced or…
- Trial name
- JASINT1 (NCT01599013)
- Testing
- Vinflunine, Gemcitabine, Vinflunine, Carboplatin
- Where
- France
- Volunteers
- 69 people
- Sponsor
- Pierre Fabre Medicament
Urothelial Cancer, Urinary Bladder Neoplasms
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer.
- Trial name
- NCT07566156
- Testing
- Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy
- Where
- 29 sites in United States, Canada and 2 more
- Volunteers
- 390 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Urinary Bladder Cancer
Predictive Role of Microbiome in Patients With Urothelial Carcinoma
This study aims to establish the microbiota composition as a predictive tool for the response to the intravesical immunotherapy with Bacillus Calmette-Guérin (BCG) and 2 different chemotherapies schemes.
- Trial name
- NCT06675656
- Testing
- DNA extraction from urine, stool and biopsy. Isolation of serum and PBMC from peripheral blood.
- Volunteers
- 420 people
- Sponsor
- IRCCS San Raffaele
Urothelial Carcinoma
Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma
FORT-2 is designed to evaluate safety, efficacy, RP2D and PK of rogaratinib in combination with atezolizumab in patients with untreated FGFR-positive urothelial carcinoma.
- Trial name
- FORT-2 (NCT03473756)
- Testing
- Rogaratinib (BAY1163877), Atezolizumab
- Where
- 30 sites in United States, Austria and 6 more
- Volunteers
- 37 people
- Sponsor
- Bayer
High-Risk Cancer, Urothelial Carcinoma Bladder
Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer
This is a prospective randomized clinical trial in high risk urothelial bladder cancer to compare adjuvant radiotherapy versus observation after radical cyctectomy.
- Trial name
- NCT04740866
- Testing
- Adjuvant Radiotherapy
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University
Transitional Carcinoma of Urinary Bladder
Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary Bladder
Phase II Trial of concurrent administration of intravesical BCG \& Interferon in the treatment and prevention of recurrence of superficial transitional carcinoma of the urinary bladder.
- Trial name
- NCT00539773
- Testing
- BCG, Interferon
- Volunteers
- 10 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Bladder Cancer
3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Trial name
- NCT01124682
- Testing
- diagnostic cystoscopy, diffusion-weighted magnetic resonance imaging, implanted fiducial-based imaging
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Bladder Cancer
Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma
This is a single arm open- label phase II- trial evaluating safety and efficacy of paclitaxel and RAD001 in patients with metastatic urothelial bladder cancer who failed prior platin-based systemic therapy.
- Trial name
- RAD001 (NCT00933374)
- Testing
- paclitaxel, RAD001
- Where
- 6 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Bladder Urothelial Carcinoma, TURBT
Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBC
Compare the therapeutic utility of SPIES assisted TURB with WLI assisted TURB in patients with non-muscle invasive bladder cancer.
- Conditions
- Bladder Urothelial Carcinoma, TURBT, Bladder Neoplasm, Cystoscopy
- Trial name
- NCT03138824
- Testing
- SPIES assisted TURBT, WLI assisted TURBT
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Urothelial Carcinoma
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
This is an open-label, multicenter, single-arm, expanded access program (EAP) designed to provide atezolizumab access to participants with locally advanced or metastatic urothelial carcinoma that has progressed on, or is…
- Trial name
- NCT02589717
- Testing
- Atezolizumab [TECENTRIQ]
- Where
- 40 sites in United States
- Sponsor
- Genentech, Inc.
Urothelial Cancer, Bladder Cancer
SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial
The purpose of this study is to find out if SU011248 works and if it is safe in patients with advanced transitional cell carcinoma.
- Conditions
- Urothelial Cancer, Bladder Cancer, Adult
- Trial name
- SPRUCE (NCT00578526)
- Testing
- SU011248
- Where
- 5 sites in Canada
- Volunteers
- 64 people
- Sponsor
- AHS Cancer Control Alberta
Urinary Bladder Neoplasms
A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder
The main purpose of this study is to identify important treatment attributes for post-radical cystectomy (RC) treatment for participants with MIBC (Muscle-Invasive Bladder Cancer) and assess the relative importance of treatment…
- Trial name
- SNUGGLE (NCT05742867)
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Bristol-Myers Squibb
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma
- Trial name
- NCT02446600
- Testing
- Biospecimen Collection, Carboplatin, Cediranib Maleate
- Where
- 356 sites in United States, Canada and 2 more
- Volunteers
- 579 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Neoplasms
Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder
Biochemotherapy (combined immunotherapeutic drugs and chemotherapeutic drugs) has shown virtue than that use chemical or biological drugs alone in the treatment of some malignant tumor.
- Trial name
- NCT00343356
- Testing
- Trement
- Volunteers
- 138 people
- Sponsor
- LanZhou University
Carcinoma Transitional Cell
Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy
The mTOR (mammalian Target of Rapamycin) protein is the center of the mTOR pathway that plays an important role in cell growth, proliferation, survival and angiogenesis through sensing and integrating energetic signals from…
- Trial name
- BEZ235 (NCT01856101)
- Testing
- BEZ235
- Where
- 12 sites in Belgium, Luxembourg
- Volunteers
- 22 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Bladder Cancer
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
The purpose of this study is to see whether 68Gallium PSMA-PET/CT scans are an effective way to detect sites of cancer in people with metastatic bladder cancer or skin cancer.
- Trial name
- NCT05562791
- Testing
- [68Ga]PSMA, PET/CT imaging
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Urothelial Carcinoma, Bladder Cancer
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
This research study is examining the effectiveness of pembrolizumab plus cryoablation or aveluma plus cryoablation on people with urothelial carcinoma, including bladder cancer, that has spread.
- Trial name
- NCT04701918
- Testing
- Pembrolizumab, Cryoablation, Avelumab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Massachusetts General Hospital
Bladder Cancer
BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer
RATIONALE: Biological therapies, such as BCG, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00352079
- Testing
- BCG vaccine, gefitinib, quality-of-life assessment
- Where
- 6 sites in Canada
- Volunteers
- 41 people
- Sponsor
- NCIC Clinical Trials Group
Bladder Cancer
A Proposed Tetra-modal Treatment Protocol for Muscle Invasive Urothelial Carcinoma of the Urinary Bladder
In Egypt, bladder cancer has been the most common cancer during the past 50 years. In 2002, Egypt's world-standardized bladder cancer incidence was 37/ 100,000, representing approximately 30,000 new cases each year.
- Trial name
- NCT05503563
- Testing
- terta modal bladder preservation
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University